LOcAL AnD sysTEmIc pRO-InfLAmmATORy AcTIvITy Of ThE EpIcARDIAL fAT
The mechanism by which EAT can play such a significant role in various CVDs has been attributed to the recently discovered property of this tissue to release pro-inflammatory cytokines in the systemic circulation. Such pro-inflammatory mediators include interleukines, gamma interferon, or alfa tumor necrosis factor. 7, 8 Also, EAT volume was demonstrated to be significantly larger in patients with increased serum levels of highly-sensitive C-reactive protein (hs-CRP), a biomarker expressing an increased systemic inflammation, proving the role of EAT as a mediator of systemic inflammation and demonstrating that EAT is a metabolically active tissue, releasing inflammatory mediators, which act not only on local but also on systemic level. 6, 9 However, epicardial pericoronary fat was also associated in several studies with an increased systemic release of inflammatory biomarkers. Recent studies demonstrated that local EAT surrounding the coronary arteries can serve as a more reliable biomarker for coronary plaque vulnerability at that level. 10 At the same time, it has been proved that the volume of the local EAT located in the vicinity of the left atrium can be associated with the risk for AF and with the risk of AF recurrence following a successful conversion to sinus rhythm. [11] [12] [13] Furthermore, EAT secretes different adipokines and matrix metalloproteases with a pronounced fibrotic effect, stimulating the development of atrial fibrosis and structural changes in the atrial myocardium in the context of a complex atrial remodeling process, ultimately resulting in development of AF. 13 
EAT-mEDIATED InfLAmmATIOn As A mAjOR pLAyER In cvD
Two articles published in this number of JIM address the hypothesis of EAT-mediated inflammation as a major player in the determinism of CVDs. In an original article published by Cernea et al., the authors demonstrated that in diabetic patients, EAT was significantly higher in the group with decreased renal function or with reduced ejection fraction. According to the authors, EAT was significantly higher in the group with LVEF <55% as compared to the group with LVEF >55% (9.5 ± 1.9 mm vs. 7.3 ± 2.3 mm), at the same time being negatively correlated with eGFR (r = −0.293, 95% CI: −0.531 to 0.013, p = 0.33). This study indicates that an increased EAT can serve as a reliable risk marker for renal injury and for deterioration of ventricular function in diabetic patients, suggesting that EAT-mediated inflammation could act on a systemic level, influencing not only the ventricular function but also the renal one. 14 Another article published in this issue by Rat et al. presents a clinical update on the role of EAT in left atrial remodeling and genesis of AF, showing that EAT is associated not only with a higher risk for AF but also with a higher recurrence rate after successful catheter ablation of AF. 15 This interesting new hypothesis indicates a potential role of EAT in the development of atrial remodeling, similar to previous observations on the correlation between EAT and left ventricular remodeling following an acute myocardial infarction. 6 It is well-known that in the period following an acute myocardial infarction, an exacerbated inflammation is responsible for worse outcomes and ventricular remodeling. 6, 16, 17 To what extent is this the result of the local release of inflammatory mediators from the area surrounding the infarcted tissue, as well as the link between local activity of the epicardial fat and atrial remodeling in AF, remains to be established.
EpIcARDIAL fAT AnD cOROnARy pLAquE vuLnERAbILITy
While the role of EAT in the inflammation-mediated progression of coronary artery disease has been recognized, its potential role in the vulnerabilization of unstable coronary plaques is still under debate, similarly to the role of locally accumulated EAT in functional destabilization of neighboring structures, such as the atria (in which case it can trigger a new onset of AF or its recurrence) or the coronary arteries (in which case it can trigger an acute coronary event). 18, 19 An interesting approach for the study of EAT and its role in inflammation-mediated reactions is represented by the identification of specific microRNAs associated with plaque vulnerability from the samples of epicardial fat tissue collected during open heart surgery. Preliminary data suggest that such microRNAs are present in a higher amount in the close vicinity of unstable coronary plaques, indicating a potential role of locally released inflammatory mediators originating from the epicardial fat in the determinism of acute coronary syndromes. 20, 21 ImAgIng TOOLs fOR quAnTIfIcATIOn Of mETAbOLIcALLy AcTIvE fAT TIssuEs
In an attempt to identify the best imagistic method for quantification of EAT, various modern methods have been proposed and studied. Computed cardiac angiography demonstrated its superiority over cardiac magnetic resonance and traditional echocardiography, being able to quantify with high accuracy global EAT volumes and local volumes of fat surrounding different structures, such as the left and right atrium or the coronary arteries. 5, [22] [23] [24] But epicardial fat is not the only metabolically active fat involved in the development of inflammatory reactions. Pericardial fat, as well as the fat accumulated in different regions of the body, could also be easily quantified by CT and can express an increased risk for different cardiovascular events. Alternative methods for fat quantification have also been developed, relying on complex methods for post-processing cardiac CT data. Such alternatives include quantification of thoracic fat, abdominal fat, or pericardial fat. 25 However, none of them demonstrated so far a clear superiority of these approaches over epicardial fat in predicting cardiovascular risk.
This issue of JIM expresses the great interest showed recently towards epicardial fat, an imaging-derived biomarker that can serve as a reliable imagistic tool for assessing cardiovascular risk. Current studies show promising results in evaluating the role of this new biomarker to predict future cardiac events, and the two articles published on this actual topic in this issue of the journal reflect the great expectations from this new imagingderived powerful tool. However, further studies are required to validate the role of EAT as a routine biomarker in clinical settings.
